AbbVie Inc. (ABBV) announced Monday that it's reached a voluntary agreement with the Trump administration to improve drug access and affordability for Americans. In return, the pharmaceutical company gets something pretty valuable: exemption from tariffs and future pricing mandates for three years.
Here's what AbbVie is putting on the table. The company committed to providing lower prices in Medicaid while pledging a massive $100 billion in U.S.-based research and development and capital investments over the next decade. That includes significant manufacturing expansion on American soil.
The deal also includes expanded direct-to-patient offerings through TrumpRx for several important medicines. Patients will see improved access to Alphagan and Combigan (used for ocular hypertension), Humira (the blockbuster arthritis treatment), and Synthroid (for hypothyroidism). These medications will be available at lower prices through the program.
The Broader Pattern
AbbVie isn't the first pharmaceutical company to strike this type of arrangement. Last week, Johnson & Johnson (JNJ) became the latest major drugmaker to reach a deal with the Trump administration, agreeing to lower drug prices for U.S. consumers in exchange for tariff exemptions. It's becoming a template for how the administration is approaching pharmaceutical policy.
A Busy Monday for Deal-Making
Beyond the Trump administration agreement, AbbVie had a packed day of announcements. The company revealed an exclusive licensing agreement with RemeGen for RC148, a bispecific antibody currently in development for multiple advanced solid tumors.
Under the terms, AbbVie will receive exclusive rights to develop, manufacture, and commercialize RC148 everywhere outside of Greater China. RemeGen gets $650 million upfront and could receive up to $4.95 billion in milestone payments as the drug progresses through development and commercialization.
Also on Monday, AbbVie agreed to acquire a device manufacturing facility in Tempe, Arizona, from West Pharmaceutical Services (WST). The transaction, expected to close in mid-2026, includes the transfer of manufacturing facilities with multiple production lines and 3.5 mL on-body injector technology. This technology will support production of current and next-generation AbbVie immunology and neuroscience medicines.
The company plans to hire approximately 200 employees at the Arizona site and invest more than $175 million to acquire, modernize, and fully integrate the facility into its global manufacturing network. That investment aligns nicely with the broader domestic manufacturing commitments made in the Trump administration deal.
ABBV Price Action: AbbVie shares were down 0.09% at $219.85 during premarket trading on Tuesday.
